blood cancer | 2 Minute Medicine

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

Kathleen Lau - February 19, 2021

0

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

Kathleen Lau - February 18, 2021

0

#VisualAbstract Low-PV study: Adding ropeginterferon alfa-2b to phlebotomy and aspirin shows improvement in response rates for treatment of polycythaemia vera in low-risk patients

Kathleen Lau - February 12, 2021

0

#VisualAbstract Multiple Cereblon genetic alterations were associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Kathleen Lau - February 11, 2021

0

$Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma$

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

Kathleen Lau - February 5, 2021

0

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia

Kathleen Lau - February 4, 2021

0

#VisualAbstract Higher risk of mortality during COVID-19 infection among patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib at COVID-19 diagnosis

Kathleen Lau - January 29, 2021

0

#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma

Kathleen Lau - January 28, 2021

0

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

Kathleen Lau - January 22, 2021

0

#VisualAbstract Higher rate of hematologic second primary malignancies developed in multiple myeloma patients who received autologous hematopoietic stem cell transplants

Kathleen Lau - January 21, 2021

0

Pulmonary arterial pruning and longitudinal change in percent emphysema and lung…

Azithromycin does not reduce mortality in patients hospitalized with COVID-19

Antibiotic prophylaxis for UTIs in elderly patients associated with an increased…

Limiting On-Call Hours Improves Resident-Physicians’ Neurobehavioral Performance

2 Minute Medicine Rewind February 22, 2021

2 Minute Medicine Rewind February 8, 2021

2 Minute Medicine Rewind Jan 25, 2021

2 Minute Medicine Rewind January 25, 2021

2 Minute Medicine Rewind January 18, 2021

Tag: blood cancer

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

#VisualAbstract Low-PV study: Adding ropeginterferon alfa-2b to phlebotomy and aspirin shows improvement in response rates for treatment of polycythaemia vera in low-risk patients

#VisualAbstract Multiple Cereblon genetic alterations were associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia

#VisualAbstract Higher risk of mortality during COVID-19 infection among patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib at COVID-19 diagnosis

#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

#VisualAbstract Higher rate of hematologic second primary malignancies developed in multiple myeloma patients who received autologous hematopoietic stem cell transplants